# Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors

> **NCT00983398** · PHASE1,PHASE2 · UNKNOWN · sponsor: **OHSU Knight Cancer Institute** · enrollment: 17 (actual)

## Conditions studied

- Central Nervous System Embryonal Neoplasm
- Embryonal Tumor With Multilayered Rosettes, C19MC-Altered
- Germ Cell Tumor
- Medulloblastoma
- Medulloepithelioma
- Primitive Neuroectodermal Tumor
- Recurrent Childhood Central Nervous System Embryonal Neoplasm
- Recurrent Malignant Germ Cell Tumor
- Recurrent Medulloblastoma
- Recurrent Primitive Neuroectodermal Tumor

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Mannitol
- **DRUG:** Melphalan
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **DRUG:** Sodium Thiosulfate

## Key facts

- **NCT ID:** NCT00983398
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-07-09
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2021-10-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00983398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00983398, "Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00983398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*